Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia—from molecular mechanisms to clinical relevance
Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …
The regulation of FOXO1 and its role in disease progression
Y Xing, A Li, Y Yang, X Li, L Zhang, H Guo - Life sciences, 2018 - Elsevier
Cell proliferation, apoptosis, autophagy, oxidative stress and metabolic dysregulation are
the basis of many diseases. Forkhead box transcription factor O1 (FOXO1) changes in …
the basis of many diseases. Forkhead box transcription factor O1 (FOXO1) changes in …
Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors
AB Patel, T O'Hare… - Hematology/Oncology …, 2017 - hemonc.theclinics.com
Every year, more than 8000 new cases of chronic myeloid leukemia (CML) are diagnosed in
the United States. 1 BCR-ABL1, a fusion protein kinase derived from a reciprocal …
the United States. 1 BCR-ABL1, a fusion protein kinase derived from a reciprocal …
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
Deregulated activity of BCR-ABL1, a nonreceptor tyrosine kinase encoded by the fusion
gene resulting from the t (9; 22)(q34; q11) chromosomal translocation, is thought to be the …
gene resulting from the t (9; 22)(q34; q11) chromosomal translocation, is thought to be the …
A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types
KRAS-and BRAF-mutant tumors are often dependent on MAPK signaling for proliferation
and survival and thus sensitive to MAPK pathway inhibitors. However, clinical studies have …
and survival and thus sensitive to MAPK pathway inhibitors. However, clinical studies have …
Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update
Chronic myeloid leukemia (CML) is characterized by the presence of the BCR-ABL1 fusion
gene, which encodes a constitutive active tyrosine kinase considered to be the pathogenic …
gene, which encodes a constitutive active tyrosine kinase considered to be the pathogenic …
Management of chronic myeloid leukemia in advanced phase
M Bonifacio, F Stagno, L Scaffidi, M Krampera… - Frontiers in …, 2019 - frontiersin.org
Management of chronic myeloid leukemia (CML) in advanced phases remains a challenge
also in the era of tyrosine kinase inhibitors (TKIs) treatment. Cytogenetic clonal evolution …
also in the era of tyrosine kinase inhibitors (TKIs) treatment. Cytogenetic clonal evolution …
Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
A Bidikian, H Kantarjian, E Jabbour, NJ Short… - Blood cancer …, 2022 - nature.com
While the clinical impact of mutations in the ABL1 gene on response to therapy in chronic
phase chronic myeloid leukemia (CP-CML) is well established, less is known about how …
phase chronic myeloid leukemia (CP-CML) is well established, less is known about how …
The dominant role of forkhead box proteins in cancer
Forkhead box (FOX) proteins are multifaceted transcription factors that are significantly
implicated in cancer, with various critical roles in biological processes. Herein, we provide …
implicated in cancer, with various critical roles in biological processes. Herein, we provide …
Mechanisms of resistance and implications for treatment strategies in chronic myeloid leukaemia
Simple Summary Chronic myeloid leukaemia (CML) is a type of blood cancer that is
currently well-managed with drugs that target cancer-causing proteins. However, a …
currently well-managed with drugs that target cancer-causing proteins. However, a …